References
- Pathak K, Raghuvanshi S. Oral bioavailability: issues and solutions via nanoformulations. Clin Pharmacokinet. 2015;54(4):325–357.
- Zhang X, Li Z, Gao J, et al. Preparation of nanocrystals for insoluble drugs by top-down nanotechnology with improved solubility and bioavailability. Molecules. 2020;25(5):1080.
- Jansook P, Fulop Z, Ritthidej GC. Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations. Drug Dev Ind Pharm. 2019;45(4):560–567.
- Liu Y, Jiang Z, Hou X, et al. Functional lipid polymeric nanoparticles for oral drug delivery: Rapid mucus penetration and improved cell entry and cellular transport. Nanomedicine. 2019;21:102075.
- Wang Q, He L, Fan D, et al. Improving the anti-inflammatory efficacy of dexamethasone in the treatment of rheumatoid arthritis with polymerized stealth liposomes as a delivery vehicle. J Mater Chem B. 2020;8(9):1841–1851.
- Li M, Du C, Guo N, et al. Composition design and medical application of liposomes. Eur J Med Chem. 2019;164:640–653.
- Yang YS, Moynihan KD, Bekdemir A, et al. Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles. Biomater Sci. 2018;7(1):113–124.
- Bocate KP, Reis GF, de Souza PC, et al. Antifungal activity of silver nanoparticles and simvastatin against toxigenic species of Aspergillus. Int J Food Microbiol. 2019;291:79–86.
- Khan S, Setua S, Kumari S, et al. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials. 2019;208:83–97.
- Clemente N, Argenziano M, Gigliotti CL, et al. Paclitaxel-loaded nanosponges inhibit growth and angiogenesis in melanoma cell models. Front Pharmacol. 2019;10:776.
- Aytac Z, Ipek S, Erol I, et al. Fast-dissolving electrospun gelatin nanofibers encapsulating ciprofloxacin/cyclodextrin inclusion complex. Colloids Surf B Biointerfaces. 2019;178:129–136.
- Kurdtabar M, Baghestani G, Bardajee GR. Development of a novel thermo-responsive hydrogel-coated gold nanorods as a drug delivery system. Gold Bull. 2019;52(1):9–17.
- Salminen WF, Wiles ME, Stevens RE. Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway. Drug Discov Today. 2019;24(1):46–56.
- US Food and Drug Administration (FDA). Liposome drug products chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation- guidance for industry; 2018. Available from: https://www.fda.gov/media/70837/download
- US Food and Drug Administartion (FDA). Frequently Asked Questions about CDER, 2019. Available from: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/frequently-asked-questions-about-cder
- Sofias AM, Dunne M, Storm G, et al. The battle of “nano” paclitaxel. Adv Drug Deliv Rev. 2017;122:20–30.
- US Food and Drug Administartion (FDA). Guidance for industry applications covered by Section 505(b)(2); 1999. Available from: https://www.fda.gov/media/72419/download
- US Food and Drug Administration (FDA). Drug products, including biological products, that contain nanomaterials; 2017. Available from: https://www.fda.gov/media/109910/download
- US Food and Drug Administration (FDA). Abbreviated New Drug Application (ANDA) 2019. Available from: https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
- US Food and Drug Administartion (FDA). CMC considerations for 505(b)(2) applications; 2011. Available from: https://www.fda.gov/media/84010/download
- Gentine P, Bourel-Bonnet L, Frisch B. Modified and derived ethanol injection toward liposomes: development of the process. J Liposome Res. 2013;23(1):11–19.
- Abdelwahed W, Degobert G, Stainmesse S, et al. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688–1713.
- Weatherall E, Willmott GR. Applications of tunable resistive pulse sensing. Analyst. 2015;140(10):3318–3334.
- Vogel R, Pal AK, Jambhrunkar S, et al. High-resolution single particle zeta potential characterisation of biological nanoparticles using tunable resistive pulse sensing. Sci Rep. 2017;7(1):1–13.
- Sikora A, Shard AG, Minelli C. Size and ζ-potential measurement of silica nanoparticles in serum using tunable resistive pulse sensing. Langmuir. 2016;32(9):2216–2224.
- Takahashi K, Kato H, Saito T, et al. Precise measurement of the size of nanoparticles by dynamic light scattering with uncertainty analysis. Part Part Syst Charact. 2008;25(1):31–38.
- Hackley VA, Clogston JD. Measuring the hydrodynamic size of nanoparticles in aqueous media using batch-mode dynamic light scattering. Methods Mol Biol. 2011;697:35–52.
- Ravar F, Saadat E, Gholami M, et al. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation. J Control Release. 2016;10;229:10–22.
- Peretz Damari S, Shamrakov D, Varenik M, et al. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes. Int J Pharm. 2018;547(1-2):648–655.
- Nothnagel L, Wacker MG. How to measure release from nanosized carriers? Eur J Pharm Sci. 2018;120:199–211.
- Muthu MS, Feng S-S. Pharmaceutical stability aspects of nanomedicines. Nanomedicine (Lond). 2009;4(8):857–860.
- Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;30;63(6):456–469.
- Weiner N, Martin F, Riaz M. Liposomes as a drug delivery system. Drug Dev Ind Pharm. 1989;15(10):1523–1554.
- ICH. Impurities: guideline for residual solvents Q3C(R6) 2016. Available from: https://database.ich.org/sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf
- Amoabediny G, Haghiralsadat F, Naderinezhad S, et al. Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: a comprehensive review. Int J Polym Mater Polym Biomater. 2018;67(6):383–400.
- Ding N, Wang Y, Chu W, et al. Improving plasma stability and antitumor effect of gemcitabine via PEGylated liposome prepared by active drug loading. J Drug Delivery Sci Technol. 2020;57:101538.
- Szczęch M, Szczepanowicz K. Polymeric core-shell nanoparticles prepared by spontaneous emulsification solvent evaporation and functionalized by the layer-by-layer method. Nanomaterials (Basel). 2020;10(3):496.
- Wang N, Chen X-C, Ding R-L, et al. Synthesis of high drug loading, reactive oxygen species and esterase dual-responsive polymeric micelles for drug delivery. RSC Adv. 2019;9(5):2371–2378.
- Pillai O ,Panchagnula R. Polymers in drug delivery. Curr Opin Chem Biol. 2001;5:447–451.
- Dadwal A, Baldi A, Kumar Narang R. Nanoparticles as carriers for drug delivery in cancer. Artif Cells Nanomed Biotechnol. 2018;46(sup2):295–305.
- Sun X, Yan X, Jacobson O, et al. Improved tumor uptake by optimizing liposome based RES blockade strategy. Theranostics. 2017;7(2):319–328.
- Liu L, Hitchens TK, Ye Q, et al. Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid. Biochim Biophys Acta. 2013;1830(6):3447–3453.
- Tang Y, Wang X, Li J, et al. Overcoming the reticuloendothelial system barrier to drug delivery with a “Don’t-Eat-Us” strategy. ACS Nano. 2019;13(11):13015–13026.
- Muthu MS, Wilson B. Challenges posed by the scale-up of nanomedicines. Nanomedicine (Lond). 2012;7(3):307–309.
- Galindo-Rodríguez SA, Puel F, Briançon S, et al. Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. Eur J Pharm Sci. 2005;25(4–5):357–367.
- Agrahari V, Agrahari V. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. Drug Discov Today. 2018;23(5):974–991.
- Desai N. Challenges in development of nanoparticle-based therapeutics. Aaps J. 2012;14(2):282–295.
- US Food and Drug Administration (FDA). Guidance for Industry PAT – a framework for innovative pharmaceutical development, manufacturing, and quality assurance; 2004. Available from: https://www.fda.gov/media/71012/download
- Hinz DC. Process analytical technologies in the pharmaceutical industry: the FDA’s PAT initiative. Anal Bioanal Chem. 2006;384(5):1036–1042.
- ICH. ICH Harmonised Tripartite Guideline Pharmaceutical Quality System Q10; 2008. Available from: https://database.ich.org/sites/default/files/Q10%20Guideline.pdf
- US Food and Drug Administartion (FDA). Scale-up & technology transfer as a part of pharmaceutical quality systems; 2011. Available from: https://www.fda.gov/media/83085/download
- Charcosset C, Juban A, Valour J-P, et al. Preparation of liposomes at large scale using the ethanol injection method: effect of scale-up and injection devices. Chem Eng Res Des. 2015;94:508–515.
- Liu D, Zhang H, Fontana F, et al. Current developments and applications of microfluidic technology toward clinical translation of nanomedicines. Adv Drug Deliv Rev. 2018;128:54–83.
- Webb C, Forbes N, Roces CB, et al. Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP: a case study using protein-loaded liposomes. Int J Pharm. 2020;582:119266.
- Ranjan AP, Mukerjee A, Helson L, et al. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnol. 2012;10(1):38.
- Shaal Rhm LA, Shegokar R. SmartCrystal combination technology – scale up from lab to pilot scale and long term stability. Pharmazie. 2010;65:877–884.
- US Food and Drug Administration (FDA). VYXEOS (daunorubicin and cytarabine) liposome for injection NDA 209401 summary basis of approval; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
- US Food and Drug Administration (FDA). CINVANTI (aprepitant) injectable emulsion NDA 209296 summary basis of approval; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209296s000lbl.pdf
- US Food and Drug Administration (FDA). SUBLOCADE (buprenorphine extended‐release) injection NDA 209819 summary basis of approval; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf
- US Food and Drug Administration (FDA). Doxorubicin hydrochloride liposome injection ANDA 208657 summary basis of approval; 2017. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208657
- US Food and Drug Administration (FDA). ARIKAYCE (amikacin liposome inhalation suspension) NDA 207356 summary basis of approval; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207356s000lbl.pdf
- US Food and Drug Administration (FDA). ARISTADA INITIO™ (aripiprazole lauroxil) extended-release injectable suspension NDA 209830 summary basis of approval; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209830lbl.pdf
- US Food and Drug Administration (FDA). ONPATTRO (patisiran) lipid complex injection NDA 210922 summary basis of approval; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf